Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Malaria vaccine developments.

Vasee S Moorthy1, Michael F Good, Adrian V S Hill

  • 1MRC Laboratories, Banjul, The Gambia. vmoorthy@malariavaccine.org

Lancet (London, England)
|January 17, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of cross-stage, cross-species malaria CD8<sup>+</sup> T cell antigens.

Nature·2026
Same author

Bivalent virus-like particles expressing SPECT1 and CSP trigger pre-erythrocytic malaria immunity and protect against transgenic <i>Plasmodium falciparum</i> sporozoite challenge in mice.

Frontiers in immunology·2026
Same author

Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adults.

Wellcome open research·2026
Same author

African-specific genetic loci determine iron status and risk of severe malaria and bacteremia in African children.

Nature communications·2026
Same author

Recent Advances, Bottlenecks, and Future Directions in <i>Plasmodium falciparum</i> Vaccine Development.

Vaccines·2026
Same author

B and T cell responses to pre-erythrocytic R21/Matrix-M and blood-stage RH5.1/Matrix-M malaria vaccines in endemic settings.

Frontiers in immunology·2026
Same journal

Convergence of metabolic risk in obesity and normal BMI: does risk disappear?

Lancet (London, England)·2026
Same journal

Metabolic traits in obesity and normal BMI in industrialised countries: a multi-country analysis of national population-based studies.

Lancet (London, England)·2026
Same journal

Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.

Lancet (London, England)·2026
Same journal

The US Ebola response and the future of global health leadership.

Lancet (London, England)·2026
Same journal

Daniel Mason: a tale of change.

Lancet (London, England)·2026
Same journal

The 2026 Wakley-Wu Lien Teh Prize Essay: why medicine, and why stay?

Lancet (London, England)·2026
See all related articles

Developing an effective malaria vaccine is crucial as malaria mortality rates remain high. Recent advances in vaccine technology offer cautious optimism for a deployable malaria vaccine in the medium to long term.

Area of Science:

  • * Malariology and Vaccinology
  • * Infectious Disease Control
  • * Global Public Health

Background:

  • * Malaria mortality rates have risen after initial declines, with 2-3 million deaths annually.
  • * Current control methods like insecticide-treated bednets and chemotherapy are insufficient alone.
  • * An effective malaria vaccine remains a critical unmet need in global health.

Purpose of the Study:

  • * To review progress in malaria vaccine development over the past five years.
  • * To assess the realistic expectations for a malaria vaccine.
  • * To identify strategies for accelerating vaccine development and deployment.

Main Methods:

  • * Review of recent advances in vaccine technology and immunology.
  • * Evaluation of novel approaches for vaccine development, using malaria as a model.

Related Experiment Videos

  • * Analysis of factors influencing the timeline and feasibility of malaria vaccine deployment.

    • Main Results:

    • * Significant progress has been made in developing malaria subunit vaccines.
    • * Novel vaccine strategies are being tested, showing potential for broad applicability.
    • * Cautious optimism exists regarding the development of a deployable malaria vaccine.

    Conclusions:

    • * An effective malaria vaccine is a realistic medium-to-long-term goal.
    • * Sufficient funding is essential to accelerate development and deployment.
    • * Continued investment in malaria vaccine research is vital for global health security.